Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Primary Amyloidosis
Conditions
Recurrent Primary Amyloidosis
Trial Timeline
Aug 25, 2017 → Dec 7, 2023
NCT ID
NCT03252600About Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide
Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide is a phase 2 stage product being developed by Bristol Myers Squibb for Recurrent Primary Amyloidosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03252600. Target conditions include Recurrent Primary Amyloidosis.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Primary Amyloidosis were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03252600 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Recurrent Primary Amyloidosis